The genetic absence of YBX1 in an MPN mouse model driven by JAK2-V617F prevented disease formation and importantly, also allowed for ruxolitinib treatment to lead to molecular remission, which was not seen when YBX1 was present. This evidence concerns the gene JAK2 and myeloproliferative disorder.